FXYD6

Summary

FXYD6 (FXYD domain containing ion transport regulator 6, HGNC:4030) is a protein-coding gene on chromosome 11q23.3, encoding FXYD domain-containing ion transport regulator 6 (Q9H0Q3). Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane.

This gene encodes a member of the FXYD family of transmembrane proteins. This particular protein encodes phosphohippolin, which likely affects the activity of Na,K-ATPase. Multiple alternatively spliced transcript variants encoding the same protein have been described. Related pseudogenes have been identified on chromosomes 10 and X. Read-through transcripts have been observed between this locus and the downstream sodium/potassium-transporting ATPase subunit gamma (FXYD2, GeneID 486) locus.

Source: NCBI Gene 53826 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 6 total
• MANE Select transcript: NM_022003

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4030
Approved symbol	FXYD6
Name	FXYD domain containing ion transport regulator 6
Location	11q23.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000137726
Ensembl biotype	protein_coding
OMIM	606683
Entrez	53826

Gene structure

Transcript identifiers

Ensembl transcripts: 63 — 55 protein_coding, 5 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000260282, ENST00000524656, ENST00000524841, ENST00000526014, ENST00000527053, ENST00000527429, ENST00000527717, ENST00000529335, ENST00000530956, ENST00000534125, ENST00000539526, ENST00000540359, ENST00000579486, ENST00000583233, ENST00000583660, ENST00000584230, ENST00000584394, ENST00000902933, ENST00000902934, ENST00000902935, ENST00000902936, ENST00000902937, ENST00000902938, ENST00000902939, ENST00000902940, ENST00000902941, ENST00000902942, ENST00000902943, ENST00000902944, ENST00000902945, ENST00000902946, ENST00000902947, ENST00000902948, ENST00000902949, ENST00000902950, ENST00000902951, ENST00000902952, ENST00000902953, ENST00000902954, ENST00000902955, ENST00000902956, ENST00000902957, ENST00000902958, ENST00000902959, ENST00000902960, ENST00000902961, ENST00000902962, ENST00000912676, ENST00000941139, ENST00000941140, ENST00000941141, ENST00000941142, ENST00000941143, ENST00000941144, ENST00000941145, ENST00000941146, ENST00000941147, ENST00000941148, ENST00000941149, ENST00000941150, ENST00000941151, ENST00000941152, ENST00000941153

RefSeq mRNA: 5 — MANE Select: NM_022003 NM_001164831, NM_001164832, NM_001164836, NM_001164837, NM_022003

CCDS: CCDS8387

Canonical transcript exons

ENST00000526014 — 8 exons

Exon	Start	End
ENSE00001130048	117836981	117838277
ENSE00002155235	117876592	117876658
ENSE00003488781	117840319	117840368
ENSE00003549740	117841990	117842028
ENSE00003627783	117839781	117839830
ENSE00003642452	117841791	117841865
ENSE00003786068	117841148	117841184
ENSE00003787656	117842719	117842781

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 99.62.

FANTOM5 (CAGE): breadth broad, TPM avg 11.5342 / max 629.6528, expressed in 717 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
122534	26.7508	727
122529	3.5332	223
122530	2.4702	213
122536	1.3174	373
122537	1.2602	319
122535	0.9594	372
122539	0.5457	183
122528	0.5014	82
122538	0.4428	150
122527	0.1981	66

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	99.62	gold quality
prefrontal cortex	UBERON:0000451	99.46	gold quality
ganglionic eminence	UBERON:0004023	99.45	gold quality
ventricular zone	UBERON:0003053	99.41	gold quality
right frontal lobe	UBERON:0002810	99.40	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.35	gold quality
cerebellar hemisphere	UBERON:0002245	99.32	gold quality
cerebellar cortex	UBERON:0002129	99.31	gold quality
body of uterus	UBERON:0009853	99.27	gold quality
cingulate cortex	UBERON:0003027	99.24	gold quality
anterior cingulate cortex	UBERON:0009835	99.24	gold quality
frontal cortex	UBERON:0001870	99.23	gold quality
frontal lobe	UBERON:0016525	99.23	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	99.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.16	gold quality
orbitofrontal cortex	UBERON:0004167	99.12	gold quality
neocortex	UBERON:0001950	99.08	gold quality
cerebellum	UBERON:0002037	99.07	gold quality
left uterine tube	UBERON:0001303	99.06	gold quality
right ovary	UBERON:0002118	99.05	gold quality
left ovary	UBERON:0002119	99.01	gold quality
middle temporal gyrus	UBERON:0002771	98.95	gold quality
amygdala	UBERON:0001876	98.85	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.77	gold quality
cerebral cortex	UBERON:0000956	98.74	gold quality
tendon of biceps brachii	UBERON:0008188	98.72	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.71	gold quality
hypothalamus	UBERON:0001898	98.54	gold quality
temporal lobe	UBERON:0001871	98.53	gold quality
superior frontal gyrus	UBERON:0002661	98.47	gold quality

Single-cell (SCXA)

Detected in 20 experiment(s), a significant marker in 19.

Experiment	Marker?	Max mean expression
E-MTAB-10485	yes	1497.65
E-HCAD-5	yes	1476.28
E-MTAB-9435	yes	1411.98
E-ENAD-27	yes	399.26
E-MTAB-10553	yes	46.83
E-GEOD-134144	yes	39.44
E-HCAD-35	yes	39.44
E-HCAD-10	yes	36.75
E-MTAB-5061	yes	28.38
E-GEOD-81547	yes	25.95
E-HCAD-31	yes	25.64
E-GEOD-84465	yes	25.46
E-HCAD-1	yes	20.03
E-GEOD-81608	yes	15.92
E-MTAB-6701	yes	15.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

55 targeting FXYD6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-449B-3P	99.20	67.24	1047
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-8077	99.17	66.67	862
HSA-MIR-6510-5P	99.14	66.59	1081
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-1253	99.12	67.08	1688

Literature-anchored findings (GeneRIF, showing 9)

• Base-pair changes in FXYD6 or in associated promoter/control regions are likely to cause abnormal function or expression of phosphohippolin and to increase genetic susceptibility to schizophrenia. (PMID:17357072)
• Our findings suggest that FXYD6 is unlikely to be related to the development of schizophrenia in a Japanese population. (PMID:18455306)
• Data show that FXYD6 does not play a role in schizophrenia in the Chinese Han population. (PMID:20149392)
• these results support that FXYD6 is a susceptibility gene of schizophrenia. (PMID:21216238)
• FXYD6 gene might play an important role in schizophrenia susceptibility. (PMID:21983730)
• FXYD6 plays a critical role of in hepatocellular carcinoma disease progression. (PMID:24715268)
• FXYD6 was verified to be directly interacting with miR-137.. (PMID:26302771)
• FXYD protein isoforms differentially modulate human Na/K pump function. (PMID:33231612)
• Identification of FXYD6 as the novel biomarker for glioma based on differential expression and DNA methylation. (PMID:38093622)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fxyd6	ENSDARG00000100971
mus_musculus	Fxyd6	ENSMUSG00000066705
rattus_norvegicus	Fxyd6	ENSRNOG00000016412

Paralogs (6): FXYD5 (ENSG00000089327), FXYD3 (ENSG00000089356), FXYD2 (ENSG00000137731), FXYD4 (ENSG00000150201), FXYD7 (ENSG00000221946), FXYD1 (ENSG00000266964)

Protein

Protein identifiers

FXYD domain-containing ion transport regulator 6 — Q9H0Q3 (reviewed: Q9H0Q3)

Alternative names: Phosphohippolin

All UniProt accessions (4): E9PHZ3, E9PJ02, Q9H0Q3, J3QKN1

UniProt curated annotations — full annotation on UniProt →

Function. Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. Reduces the apparent affinity for intracellular Na(+) with no change in the apparent affinity for extracellular K(+). In addition to modulating NKA kinetics, may also function as a regulator of NKA localization to the plasma membrane.

Subunit / interactions. Regulatory subunit of the sodium/potassium-transporting ATPase which is composed of a catalytic alpha subunit, a non-catalytic beta subunit and an additional regulatory subunit. The regulatory subunit, a member of the FXYD protein family, modulates the enzymatic activity in a tissue- and isoform-specific way by changing affinities of the Na+/K+-ATPase toward Na(+), K(+) or ATP.

Subcellular location. Cell membrane.

Similarity. Belongs to the FXYD family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H0Q3-1	1	yes
Q9H0Q3-2	2

RefSeq proteins (5): NP_001158303, NP_001158304, NP_001158308, NP_001158309, NP_071286* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000272	Ion-transport_regulator_FXYD	Family
IPR047297	FXYD_motif	Conserved_site

Pfam: PF02038

UniProt features (9 total): topological domain 2, signal peptide 1, chain 1, transmembrane region 1, region of interest 1, splice variant 1, turn 1, helix 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
8D3V	ELECTRON MICROSCOPY	3.4
8D3W	ELECTRON MICROSCOPY	3.5
8D3U	ELECTRON MICROSCOPY	3.7
8D3Y	ELECTRON MICROSCOPY	3.9
8D3X	ELECTRON MICROSCOPY	4.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H0Q3-F1	70.35	0.13

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-5578775	Ion homeostasis
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-9679191	Potential therapeutics for SARS

MSigDB gene sets: 220 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, GNF2_RTN1, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_TRANSMEMBRANE_ELECTROCHEMICAL_GRADIENT, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_POTASSIUM_ION_HOMEOSTASIS, GOBP_POSITIVE_REGULATION_OF_SODIUM_ION_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, EFC_Q6, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_SODIUM_ION_TRANSPORT, ONKEN_UVEAL_MELANOMA_UP, GOBP_POSITIVE_REGULATION_OF_MONOATOMIC_ION_TRANSPORT, TGCTGAY_UNKNOWN, DELYS_THYROID_CANCER_DN, GOBP_INTRACELLULAR_POTASSIUM_ION_HOMEOSTASIS

GO Biological Process (5): potassium ion transport (GO:0006813), sodium ion transport (GO:0006814), positive regulation of sodium ion export across plasma membrane (GO:1903278), monoatomic ion transport (GO:0006811), regulation of monoatomic ion transport (GO:0043269)

GO Molecular Function (3): sodium channel regulator activity (GO:0017080), protein binding (GO:0005515), ion channel regulator activity (GO:0099106)

GO Cellular Component (5): plasma membrane (GO:0005886), presynaptic membrane (GO:0042734), postsynaptic membrane (GO:0045211), glutamatergic synapse (GO:0098978), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cardiac conduction	1
Ion channel transport	1
SARS-CoV Infections	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metal ion transport	2
synaptic membrane	2
sodium ion export across plasma membrane	1
positive regulation of sodium ion transmembrane transport	1
regulation of sodium ion export across plasma membrane	1
transport	1
monoatomic ion transport	1
regulation of transport	1
sodium channel activity	1
ion channel regulator activity	1
binding	1
monoatomic ion channel activity	1
channel regulator activity	1
membrane	1
cell periphery	1
presynapse	1
postsynapse	1
synapse	1
cellular anatomical structure	1

Protein interactions and networks

STRING

658 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FXYD6	FXYD5	Q96DB9	729
FXYD6	DRD2	P14416	588
FXYD6	TYR	P14679	549
FXYD6	EXOC1L	A0A1B0GW35	401
FXYD6	MPZL3	Q6UWV2	355
FXYD6	ITPRIPL2	Q3MIP1	353
FXYD6	GPR68	Q15743	353
FXYD6	KCNS1	Q96KK3	353
FXYD6	SULF2	Q8IWU5	351
FXYD6	LXN	Q9BS40	350
FXYD6	LDB2	O43679	350
FXYD6	COL13A1	Q5TAT6	350
FXYD6	PANX1	Q96RD7	349
FXYD6	CRIM1	Q9NZV1	347
FXYD6	HOATZ	Q6PI97	325

IntAct

189 interactions, top by confidence:

A	B	Type	Score
FXYD6	CREB3L1	psi-mi:“MI:0915”(physical association)	0.720
CREB3L1	FXYD6	psi-mi:“MI:0915”(physical association)	0.720
SVOP	FXYD6	psi-mi:“MI:0915”(physical association)	0.600
FXYD6	LHFPL5	psi-mi:“MI:0915”(physical association)	0.560
FXYD6		psi-mi:“MI:0915”(physical association)	0.560
FXYD6	FFAR2	psi-mi:“MI:0915”(physical association)	0.560
FXYD6	RNASEK	psi-mi:“MI:0915”(physical association)	0.560
FXYD6	SLC35E3	psi-mi:“MI:0915”(physical association)	0.560
MFF	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
CD74	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
SLC30A2	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
SLC47A1	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
TMEM237	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
DERL2	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
APCDD1L	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
RHBDL1	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
CLEC10A	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
FXYD6	CERS4	psi-mi:“MI:0915”(physical association)	0.560
ELOVL4	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
TM4SF18	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
TMEM35A	FXYD6	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (124): CREB3L1 (Two-hybrid), FXYD6 (Two-hybrid), FXYD6 (Affinity Capture-MS), FXYD6 (Affinity Capture-MS), FXYD6 (Two-hybrid), FXYD6 (Two-hybrid), HAUS2 (Two-hybrid), CCDC90B (Two-hybrid), TRIM27 (Two-hybrid), SLC35E1 (Two-hybrid), FXYD6 (Two-hybrid), FXYD6 (Two-hybrid), FXYD6-FXYD2 (Two-hybrid), FXYD6 (Two-hybrid), FXYD6 (Two-hybrid)

ESM2 similar proteins: A0A1B0GW64, A2AFR3, A4IFL2, A6QLZ5, A8MVS5, A8MWV9, E1BBQ2, E9Q2Z6, O54693, O73612, P01134, P0C8R9, P18519, P48030, P52795, P52796, P98172, Q0VAQ4, Q0VBP7, Q14CM0, Q15223, Q3MHZ5, Q4FZH1, Q4R566, Q5JRV8, Q5R8M2, Q5RB29, Q5T1S8, Q5T292, Q5VX71, Q6AYP5, Q7TPF1, Q8BHW5, Q8BR63, Q8CA71, Q8IVY1, Q8R5M8, Q91WM6, Q91XV6, Q96DD7

Diamond homologs: C0HJJ0, P58550, Q3MHZ5, Q3SZX0, Q4R566, Q5RB29, Q63113, Q91XV6, Q9D164, Q9D2W0, Q9H0Q3, W5P3P0, G1TZA0, I3LMB3, O00168, O08589, O13001, O97797, P54710, P56513, P58549, P59645, P59646, P59647, P59648, P59649, Q04645, Q04646, Q04679, Q04680, Q14802, Q3ZBJ3, Q61835, Q96DB9, Q9Z239, P97808

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

6 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	6
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1565 predictions. Top by Δscore:

Variant	Effect	Δscore
11:117839826:TGTTG:T	acceptor_gain	1.0000
11:117839831:C:CC	acceptor_gain	1.0000
11:117840252:T:TA	donor_gain	1.0000
11:117840366:GCC:G	acceptor_gain	1.0000
11:117840367:CC:C	acceptor_gain	1.0000
11:117840367:CCC:C	acceptor_gain	1.0000
11:117840368:CC:C	acceptor_gain	1.0000
11:117841787:TTA:T	donor_loss	1.0000
11:117841788:TACTT:T	donor_loss	1.0000
11:117841789:A:AC	donor_gain	1.0000
11:117841789:A:T	donor_loss	1.0000
11:117841790:C:CG	donor_gain	1.0000
11:117841790:CT:C	donor_gain	1.0000
11:117841790:CTT:C	donor_gain	1.0000
11:117841790:CTTA:C	donor_gain	1.0000
11:117841793:A:AC	donor_gain	1.0000
11:117841863:AATC:A	acceptor_loss	1.0000
11:117841864:ATC:A	acceptor_loss	1.0000
11:117841865:TC:T	acceptor_loss	1.0000
11:117841865:TCTG:T	acceptor_loss	1.0000
11:117841866:C:CC	acceptor_gain	1.0000
11:117841866:C:CG	acceptor_loss	1.0000
11:117841986:TCACC:T	donor_loss	1.0000
11:117841987:CA:C	donor_loss	1.0000
11:117841988:A:AT	donor_loss	1.0000
11:117842026:CTG:C	acceptor_gain	1.0000
11:117842027:TG:T	acceptor_gain	1.0000
11:117842029:C:CC	acceptor_gain	1.0000
11:117842713:ACTT:A	donor_loss	1.0000
11:117842714:CTT:C	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000051671 (11:117847999 A>G), RS1000121950 (11:117855038 T>A), RS1000227894 (11:117838249 G>A,C), RS1000270864 (11:117876994 G>T), RS1000367387 (11:117866249 C>T), RS1000410324 (11:117855345 C>G,T), RS1000416177 (11:117860321 A>C,G), RS1000511273 (11:117870805 C>T), RS1000539118 (11:117837205 C>G,T), RS1000761057 (11:117870669 G>A), RS1000864361 (11:117859211 T>A,C,G), RS1000883777 (11:117865954 C>G,T), RS1000884798 (11:117841984 G>A,T), RS1000942489 (11:117848295 G>A), RS1001008289 (11:117836898 C>A,T)

Disease associations

OMIM: gene MIM:606683 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003997_18	Myopia	1.000000e-11
GCST006993_11	Hippocampal volume in Alzheimer’s disease dementia	1.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005035	hippocampal volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
Decitabine	affects expression, affects cotreatment	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
TL8-506	increases expression, affects cotreatment	1
methylmercuric chloride	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
beta-lapachone	decreases expression	1
sodium arsenite	affects methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
gardiquimod	increases expression, decreases reaction	1
Vorinostat	affects expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Carbamazepine	affects expression	1
Cisplatin	affects expression	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	1
Poly I-C	affects cotreatment, increases expression	1
Silicon Dioxide	decreases expression	1
Dronabinol	increases expression	1
Thimerosal	decreases expression	1
Tunicamycin	decreases expression	1
Vitamin E	increases expression	1
Aflatoxin B1	increases methylation	1
Asbestos, Crocidolite	decreases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.